Insight on Sun Pharma’s Licensing Agreement with Ferring Pharmaceutical for Caritec in India
Sun Pharmaceutical Industries entered into a licensing agreement with Ferring Pharmaceuticals to commercialise innovative obstetric drug Caritec in India. One of the... Read More
Eli Lilly to partner with Cipla, Lupin, Sun Pharma to manufacture, distribute Baricitinib in India
US drug-maker Eli Lilly, on May 10, announced that it had issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of... Read More
Sun Pharma launches generic Glumetza tablets in US
Sun Pharmaceutical Industries Ltd announced that one of its wholly owned subsidiaries has launched the generic versions of Glumetza (metformin hydrochloride) extended... Read More
Sun Pharma’s got clearance For Halol Facility From US Regulator
Sun Pharma received the EIR or Establishment Inspection Report from the US Food and Drug Administration (FDA) for its Halol facility in... Read More
Sun Pharma submitted BLA in USFDA for tildrakizumab to treat plaque psoriasis
Sun Pharmaceutical Industries Ltd, announced the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for tildrakizumab. The... Read More
Sun Pharma’s subsidiary Taro Pharmaceuticals acquired Thallion, including the rights to the drug candidate Shigamab
India largest drug maker Sun Pharma’s subsidiary Taro Pharmaceuticals has entered into an agreement with Canadian biopharmaceutical firm Bellus Health to buy... Read More
Sun Pharma to acquire Novartis’s branded drug Odomzo
Posted on23 Dec 2016
Comments0
Sun Pharmaceutical Industries Ltd will acquire the NOVARTIS’s branded cancer drug Odomzo for an upfront payment of $175 million. Odomzo is the... Read More
Sun Pharma – Moebius Medical signed co-development deal for osteoarthritis drug
Pharma major Sun Pharmaceutical Industries and Israel-based Moebius Medical signed an exclusive global licensing deal to develop liposomal non-opioid pain product for... Read More
Sun Pharma received 483 observation for Mohali Plant
Posted on25 Nov 2016
Comments0
Reason for 483 observation issued: Deviation from manufacturing standard About Plant: Â The Mohali facility, which belonged to Ranbaxy Laboratories Ltd, has been... Read More
Sun Pharma’s Strategic Expansion in Russia: To acquire majority stake in Russia’s Biosintez
Sun Pharmaceutical Industries Ltd has agreed to acquire an 85.1% stake in Russian drugmaker JSC Biosintez as part of its strategy to... Read More